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Accepted 7 January 2013AbstractObjectives: Estimates of treatment effectiveness in epidemiologic studies using large observational health care databases may be biased
owing to inaccurate or incomplete information on important confounders. Study methods that collect and incorporate more comprehensive
confounder data on a validation cohort may reduce confounding bias.
Study Design and Setting: We applied two such methods, namely imputation and reweighting, to Group Health administrative data
(full sample) supplemented by more detailed confounder data from the Adult Changes in Thought study (validation sample). We used in-
fluenza vaccination effectiveness (with an unexposed comparator group) as an example and evaluated each method’s ability to reduce bias
using the control time period before influenza circulation.
Results: Both methods reduced, but did not completely eliminate, the bias compared with traditional effectiveness estimates that do not
use the validation sample confounders.
Conclusion: Although these results support the use of validation sampling methods to improve the accuracy of comparative effective-
ness findings from health care database studies, they also illustrate that the success of such methods depends on many factors, including the
ability to measure important confounders in a representative and large enough validation sample, the comparability of the full sample and
validation sample, and the accuracy with which the data can be imputed or reweighted using the additional validation sample informa-
tion.  2013 Elsevier Inc.
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Large health care databases are increasingly being used
to study treatment effectiveness in medical research [1].
However, using data collected primarily for administrative
and clinical purposes to conduct comparative effectiveness
research poses many challenges. One major problem is that
large databases can have limited ability to characterize im-
portant confounding differences in outcome risk between
exposed and unexposed persons [2e4]. For instance, data-
base confounder adjustment for health status is often ac-
complished by broadly defining medical conditions usingConflict of interest: L.A.J. has received research funding from Sanofi
Pasteur, Pfizer, Novartis, and GlaxoSmithKline.
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Open access under CC BY-NC-ND license.binary International Classification of Disease (ICD-9) diag-
nosis codes, or risk score summary measures based on these
codes, assigned by the medical provider during patient
visits [5e7]. This relatively crude adjustment can lead to
residual confounding in effectiveness estimates because
ICD-9 codes do not adequately measure disease severity
or functional status [4,8e12].
A prominent example of this problem is the estimation
of influenza vaccine effectiveness (VE) among the elderly
in large database studies, which have consistently found
implausibly high-risk reductions against all-cause mortality
(|50%) when adjusting only for database information such
as binary ICD-9-coded indicators of health status [13e15].
More recent research has indicated that residual confound-
ing may account for some, if not all, of this observed effect
[10,11]. Specifically, when examining the association be-
tween influenza vaccine and mortality in the preinfluenza
control period before the circulation of influenza, even
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 Use of validation sampling methods, such as impu-
tation or reweighting, can improve the accuracy of
comparative effectiveness findings from large
health care database studies, which can have lim-
ited ability to characterize important confounding
differences in outcome risk between exposed and
unexposed persons.
 The association between influenza vaccination and
risk of all-cause mortality is a useful example for
studying confounding in treatment effectiveness
studies that rely on administrative databases, as
there is strong confounding and a natural control
period before influenza season that can be used
to assess bias and the ability of more sophisticated
methods (like those that use validation sampling)
to reduce it.
 The success of validation sampling methods in
practice depends on many factors, including the
ability to measure important confounders in a large
enough validation sample, the comparability of the
full sample and validation sample, and the accu-
racy with which the data can be imputed or re-
weighted using the additional validation sample
information.
 Without clear gold-standard estimates of effective-
ness in practice for most exposures, a balance of
simulation studies (where truth can be generated)
and example applications (where the complexities
of real data are present) is needed to more fully un-
derstand the optimal implementation and settings
for use of validation methods in large health care
database studies.
larger reductions in risk (|70%) have been found [10]. Any
effect observed during the preinfluenza period represents
bias because no association between influenza vaccine
and morbidity or mortality is biologically plausible when
influenza virus is not circulating. This bias has been shown
to be reduced by adjusting for functional limitations ob-
tained from medical chart review [11], which suggests that
unmeasured frailty is the most plausible unmeasured con-
founder in this setting. Such confounding would occur if se-
niors who are very close to dying are no longer given
preventive therapies, such as influenza vaccine.
Although adjusting more comprehensively for additional
confounders obtained by medical record review or in-
person physical examination has the potential to reduce
bias in traditional effectiveness estimates that adjust only
for information available in database sources, it may be
too expensive to collect these more costly confounders inlarge database studies, where sample sizes can reach tens
or hundreds of thousands. One solution is to collect the
more expensive data on a smaller validation sample or
a subset of the full database cohort and use validation or
two-phase sampling methods to incorporate this informa-
tion into analyses. Herein, we implement two such ap-
proaches, a missing data imputation method and a survey
sample reweighting method, to estimate influenza VE in
the elderly. We use Group Health Cooperative (GHC) ad-
ministrative data from a prior influenza VE study [10] (full
sample) supplemented by richer confounder data on a subset
(validation subsample) that included in-person examina-
tions as part of the Adult Changes in Thought (ACT) study
[16]. We use the control time period before influenza sea-
son to evaluate each method’s ability to successfully reduce
confounding bias compared with traditional adjustment ap-
proaches that rely solely on confounders from database
sources.2. Materials and methods
2.1. Study design, setting, and population
We used existing cohorts from two prior studies con-
ducted among persons aged 65 years and older who were
members of GHC, a managed care organization in Wash-
ington State with |350,000 enrollees. The composition of
the GHC population is representative of the surrounding re-
gion, which is primarily white, middle class, and well edu-
cated. The first was a large, retrospective database cohort
study of influenza VE among 72,527 community-dwelling
seniors from 1995 to 2002 [10] that captured data from
GHC’s administrative systems on all-cause mortality (out-
come of interest), influenza immunization (exposure of in-
terest), and database confounders used in prior database
studies of influenza VE [14,15], including health care utili-
zation (e.g., number of outpatient visits) and ICD-9 diagno-
sis codes assigned to patient encounters and used to define
binary health status indicators (e.g., heart disease). In the
present study, we used data from 2 study years (September
1, 2000eAugust 31, 2001 and September 1, 2001eAugust
31, 2002), required that persons remain continuously en-
rolled during each study year, and defined this cohort as
the full sample. Subjects were followed each study year
from the September 1 start date until their death or August
31, whichever occurred first. Database confounders were
captured in the 1-year baseline period before each study
year (September 1, 1999eAugust 31, 2000 and September
1, 2000eAugust 31, 2001). To make fuller use of available
database information in the present study compared with
prior studies, we also defined additional database covariates
using a broader range of data, including medications, labo-
ratory test results, other health care utilization (e.g., home
health services), and disease severity measures, based on
methods described previously [11].
Table 1. Study and subject characteristics by study year
Study year (September through August)
Full sample ACT validation sample
2000 2001 2000 2001
Number of cohort members evaluated 43,814 43,974 1,005 968
Total person-years assessed 43,140 43,260 984 952
Number of deaths 1,406 1,464 40 31
Number of vaccinations 31,417 32,005 789 745
Date by which at least x% of influenza vaccinations given to study cohort members during the study year had been administered
50 November 21 November 10 December 1 November 10
75 December 5 November 15 December 6 November 15
90 December 11 November 27 December 9 November 26
Vaccination coverage in the study cohort, as of December 31 (%) 70 72 76 76
Abbreviation: ACT, Adult Changes in Thought study.
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ACT study, a prospective cohort study of aging and demen-
tia among GHC seniors [16]. The original ACT cohort of
2,581 community-dwelling, dementia-free persons aged
65 years or older was enrolled from 1994 to 1996 and sup-
plemented with 811 more members from 2000 to 2003.
Extensive data from in-person interviews and physical ex-
aminations were collected at an initial visit and follow-up
visits every 2 years thereafter, including self-reported de-
mographics, activities, and instrumental activities of daily
living (ADL and IADL), health behaviors, and disease con-
ditions, as well as clinical assessments of physical function,
dementia, and depression. Some interviews were conducted
by proxy if study subjects were unavailable. Further study
design details have been published previously [16,17]. In
the present study, we used ACT data to more comprehen-
sively characterize potential confounders on subjects who
were also in the full sample. Confounder data were ac-
cessed on ACT enrollees with a follow-up visit during the
baseline period in which database confounders were avail-
able from the full sample (September 1, 1999eAugust 31,Fig. 1. Timing of influenza circulation and distribution of influenza
vaccine. ACT, Adult Changes in Thought study.2001 and September 1, 2000eAugust 31, 2001). These
ACT participants are a subset of the full cohort and are
defined in the present study as the validation sample. In
analyses, we linked the ACT data on validation sample
members to their full sample database information, which
contained their mortality status, influenza vaccine exposure
status, and database confounders.2.2. Statistical model
Our primary aim was to assess whether confounding
bias in traditional database estimates of influenza VE
against all-cause mortality, which naively adjust only for
database confounders, can be reduced by incorporating ad-
justment for additional confounders measured in a valida-
tion sample. For each approach, we used data from both
study years to fit a Cox proportional hazards model that es-
timated the relative risk (RR) of death for vaccinated vs.
unvaccinated individuals, treating vaccination status as a bi-
nary timeevarying covariate defined for each subject as
‘‘unvaccinated’’ from September 1 up to the date of vacci-
nation and as ‘‘vaccinated’’ for the rest of that study year
(i.e., until August 31). To estimate the effect of vaccine dur-
ing influenza season and control periods before and after-
ward, we included an interaction term between vaccine
status and a three-category time period effect defined using
local influenza viral surveillance data for each study year
[10]: before (September 1 to December 16 in study year
1 and September 1 to December 15 in study year 2), during
(December 17 to March 18 in study year 1 and December
16 to March 10 in study year 2), and after (March 19 to Au-
gust 31 in study year 1 and March 11 to August 31 in study
year 2) influenza season.
In each Cox model, propensity scores were used to con-
solidate confounders into a single summary measure for ad-
justment. The propensity score was defined as the
probability of receiving influenza vaccine in each study
year conditional on confounders measured in the year prior
and was estimated using multivariable logistic regression.
Two specific scores were created using confounders defined
a priori based on expert clinical opinion: (1) An error-prone
score (PSep) computed among the full cohort and based
Table 2. Study characteristics of the full database cohort and validation sample based on database confounders
Characteristics
Full sample ACT validation sample
Vaccinated
person-years (%)
Unvaccinated
person-years (%)
Total
person-years (%)
Vaccinated
person-years (%)
Unvaccinated
person-years (%)
Total
person-years (%)
Total person-years 49,141 37,259 86,400 1,180 756 1,936
Age group (yr)
65e74 49.8 53.5 51.4 25.7 24.9 25.4
70e84 40.7 36.1 38.7 57.9 54.5 56.6
85þ 9.6 10.4 9.9 16.4 20.5 18.0
Sex
Male 42.5 42.2 42.3 40.8 38.8 40.0
Female 57.5 57.8 57.7 59.2 61.2 60.0
Prescriptions in previous year
0e14 20.7 31.2 25.2 16.1 21.3 18.1
15e33 24.7 24.8 24.7 23.6 26.4 24.7
34e63 26.8 22.9 25.1 29.4 26.0 28.1
64 27.8 21.1 24.9 30.9 26.2 29.0
Medication
Prednisone 6.1 4.9 5.6 5.8 5.9 5.9
Isosorbide di- or mononitrate 3.0 2.4 2.7 3.4 3.0 3.2
Furosemide 12.7 11.0 12.0 15.4 14.4 15.0
ACE inhibitors 26.3 22.8 24.8 25.3 22.3 24.1
Verapamil, diltiazem, or felodipine 16.0 13.4 14.9 17.8 15.1 16.8
Antidepressants 21.2 18.9 20.2 23.2 21.8 22.7
Oral narcotics 10.9 9.5 10.3 20.3 17.6 19.2
Benzodiazepine 17.6 15.3 16.6 22.7 18.7 21.2
Pulmonary medications 4.8 3.6 4.3 4.7 3.3 4.2
Medical services received in previous year
Chemotherapy or radiation treatment 0.4 0.4 0.4 0.4 0.4 0.4
Home health care 8.3 7.5 7.9 7.3 7.4 7.3
Optometrist 54.4 48.0 51.6 52.6 46.2 50.1
Hospitalization
None 84.5 86.3 85.3 83.9 86.8 85.0
1þ 15.5 13.7 14.7 16.1 13.2 15.0
Total specialist visits
None 66.1 71.7 68.5 56.5 63.7 59.3
1þ 33.9 28.3 31.5 43.5 36.3 40.7
Days with one or more outpatient visits
0e3 20.7 30.4 24.9 14.2 21.6 17.1
4e6 20.8 21.4 21.1 16.2 18.5 17.1
7e12 30.3 26.7 28.8 34.7 31.7 33.5
13þ 28.2 21.5 25.3 35.0 28.3 32.3
Medical diagnosis in previous year
Asthma 5.1 4.1 4.7 5.4 4.3 4.9
Congestive heart failure 6.2 5.5 5.9 7.7 7.2 7.5
COPD 11.4 9.4 10.5 11.2 9.8 10.7
Dementia 2.1 2.6 2.3 3.0 5.8 4.1
Depression 5.5 4.9 5.3 5.4 5.5 5.5
(Continued )
S
1
1
3
J.C
.
N
elso
n
et
a
l.
/
Jo
u
rn
a
l
o
f
C
lin
ica
l
E
p
id
em
io
log
y
6
6
(2
0
1
3
)
S
1
1
0e
S
1
2
1
Table 2. Continued
Characteristics
Full sample ACT validation sample
Vaccinated
person-years (%)
Unvaccinated
person-years (%)
Total
person-years (%)
Vaccinated
person-years (%)
Unvaccinated
person-years (%)
Total
person-years (%)
Peripheral vascular disease 3.0 2.5 2.8 3.9 2.7 3.5
Pneumonia 4.2 3.8 4.0 4.4 4.7 4.5
Diabetes
None 84.8 86.8 85.6 87.1 88.9 87.8
Untreated 4.3 3.8 4.1 3.4 2.5 3.1
Oral medications only 5.0 4.5 4.8 4.0 3.8 3.9
Insulin 1.6 1.2 1.4 1.3 0.7 1.1
Complication 4.4 3.7 4.1 4.1 4.1 4.1
Cancer
None 77.5 80.5 78.8 76.4 79.5 77.6
Cancer 20.1 17.2 18.9 21.2 18.4 20.1
Severe/multiple myeloma 2.5 2.3 2.4 2.4 2.1 2.3
Laboratory values in previous year
Lowest albumin
!3.39 1.3 1.2 1.3 1.6 1.2 1.4
3.4e3.59 1.5 1.4 1.5 1.7 2.5 2.0
3.6e3.89 7.6 6.4 7.1 8.1 7.2 7.7
3.9þ 30.3 28.1 29.4 28.6 26.7 27.9
Laboratory data not assessed 59.2 62.8 60.8 60.1 62.4 61.0
Highest creatinine
!1 26.7 24.6 25.8 28.3 26.1 27.4
1.1e1.39 25.9 23.1 24.7 27.6 26.1 27.0
1.4e2.39 8.2 7.1 7.7 9.1 8.8 9.0
2.4þ 1.1 1.0 1.1 1.3 1.4 1.3
Laboratory data not assessed 38.0 44.2 40.7 33.8 37.6 35.3
Lowest hematocrit
!29 1.5 1.3 1.4 2.0 1.4 1.8
29e33.9 3.9 3.4 3.7 4.2 4.9 4.5
34e37.9 11.0 9.7 10.4 15.0 13.6 14.4
38e39.9 10.6 9.5 10.1 11.8 11.5 11.7
40þ 30.2 28.0 29.3 29.2 25.9 27.9
Laboratory data not assessed 42.7 48.1 45.0 37.8 42.6 39.7
Abbreviations: ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease.
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Table 3. Study characteristics of the validation sample based on supplemental confounders
Characteristics
ACT validation sample
Vaccinated person-years (%) Unvaccinated person-years (%) Total person-years (%)
Total person-years 1,180 756 1,936
Age group (yr)
65e74 25.7 24.9 25.4
70e84 57.9 54.5 56.6
85þ 16.4 20.5 18.0
Sex
Male 40.8 38.8 40.0
Female 59.2 61.2 60.0
Race
White 90.1 89.1 89.7
Perceived health
Poor 2.7 3.5 3.0
Fair 14.3 15.4 14.7
Good 41.5 38.8 40.5
Very good 31.5 27.9 30.1
Excellent 10.0 14.4 11.7
BMI
Underweight 0.9 1.3 1.1
Adequate 32.5 32.9 32.7
Overweight 39.1 39.0 39.0
Obese 24.6 23.2 24.1
Unavailable 2.9 3.6 3.2
Lives alone 37.1 37.3 37.2
Any exercise in past 12 mo 69.8 64.8 67.9
Frailty measures
Frail grip strength 38.5 39.3 38.8
Frail walking speed 30.5 35.0 32.2
Able to walk around house
No difficulty 88.9 88.5 88.7
Some difficulty 8.5 8.5 8.5
A lot of difficulty/unable 2.6 3.0 2.7
Able to walk half a mile
No difficulty 68.1 65.0 66.9
Some difficulty 10.6 12.5 11.3
A lot of difficulty/unable 21.2 22.5 21.7
Able to walk upstairs
No difficulty 76.2 73.7 75.2
Some difficulty 14.0 15.6 14.7
A lot of difficulty/unable 9.8 10.7 10.2
Able to get out of bed/chair
No difficulty 79.0 79.1 79.0
Some difficulty 17.5 16.9 17.2
A lot of difficulty/unable 3.6 4.0 3.8
Able to feed oneself
No difficulty 98.2 96.9 97.7
Some difficulty 1.8 3.1 2.3
Able to dress oneself
No difficulty 92.5 91.7 92.2
Some difficulty 6.2 6.3 6.3
A lot of difficulty/unable 1.2 2.0 1.5
Able to bathe oneself
No difficulty 92.9 91.2 92.2
Some difficulty 4.7 5.4 5.0
A lot of difficulty/unable 2.4 3.4 2.8
Able to use toilet
No difficulty 96.2 95.2 95.8
Some difficulty 2.8 3.6 3.1
A lot of difficulty/unable 0.9 1.2 1.0
Receives home health care 8.0 8.0 8.0
Uses handivan 4.3 4.5 4.4
Difficulty on any IADL item 30.3 33.9 31.7
(Continued )
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Table 3. Continued
Characteristics
ACT validation sample
Vaccinated person-years (%) Unvaccinated person-years (%) Total person-years (%)
Difficulty on any ADL item 28.8 29.5 29.0
Medical diagnosis in previous year
Congestive heart failure 6.9 6.4 6.7
Hearth rhythm problems 29.5 28.8 29.2
Heart condition 24.5 22.8 23.8
Diabetes
None 87.7 88.6 88.1
Untreated 2.9 2.8 2.9
With oral medication 3.5 3.6 3.5
With complications 5.9 5.0 5.6
Parkinson’s disease 3.2 3.0 3.1
Chronic lung condition 22.3 22.9 22.5
Acute lung infection 55.1 54.9 55.0
Kidney
None 89.0 88.6 88.8
Disease 9.7 10.3 9.9
Failure 1.3 1.1 1.2
Autoimmune disorder 6.3 7.0 6.6
Any fractures 10.4 10.1 10.3
Dementia 5.1 8.9 6.6
Cognitive Abilities Screening Instrument Score
0e89 18.8 23.7 20.7
90e94 29.4 29.8 29.6
95e96 18.8 17.4 18.3
97þ 32.5 28.7 31.0
CES-D score
0 28.5 26.7 27.8
1e3 32.3 34.0 33.0
4e6 13.9 13.9 13.9
6þ 25.0 24.7 24.9
Abbreviations: BMI, body mass index; IADL, instrumental activities of daily living; ADL, activities of daily living; CES-D, Center for Epidemi-
ologic Studies Depression Scale.
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score (PSgs) computed in the validation cohort and based
both on database and validation sample confounders. To
prevent bias, propensity score models excluded variables
related only to exposure and not outcome by inspecting
the age and gender-adjusted odds ratios (ORs) between
each variable and outcome [18,19]. Using these propensity
scores, we implemented four approaches, namely (1) an un-
adjusted model, (2) a na€ıvely adjusted model, (3) imputa-
tion, and (4) reweighting. The unadjusted and na€ıvely
adjusted methods involved fitting a Cox model among the
full sample that either did not adjust for any confounders
or adjusted only for database confounders as measured by
PSep, thus replicating traditional unadjusted and adjusted
database study methods. The second two approaches, de-
scribed further in the next sections, fit Cox models that in-
corporated confounders from the ACT validation sample.
2.3. Imputation
We first viewed the lack of more detailed confounder
data (i.e., the lack of PSgs) for some full cohort members
from a missing data perspective [20] and applied the fol-
lowing steps [21], (1) in the validation sample, use linearregression to estimate the association between the predic-
tor PSep and outcome PSgs, adjusted for influenza vaccina-
tion status; (2) use this regression equation to predict PSgs
among full sample members not in the ACT validation
sample; and (3) in the full sample, fit a Cox regression
model estimating the RR of death for those vaccinated
vs. not vaccinated, adjusted for PSgs (for those in the
ACT validation sample) or its predicted value of PSgs
(for those not in the ACT validation sample) and use boot-
strapping to estimate standard errors. Notably, when con-
sidering this problem in a measurement error context,
where the propensity score based only on database con-
founders (PSep) is the quantity measured with error com-
pared with a gold standard propensity score based on the
more detailed confounder data (PSgs), this imputation ap-
proach is equivalent to the regression calibration algorithm
described by Carroll et al. [22]. St€urmer et al. [21] referred
to this specific application of regression calibration as pro-
pensity score calibration.
2.4. Reweighting
The second validation sampling approach we used is
a survey reweighting method called generalized raking
Table 4. Age- and gender-adjusted odds ratios of associations between
database confounders and death in the full sample
Full sample characteristics
Association with death
Odds ratio (95% CI)
Prescriptions in previous year
0e14 Referent
15e33 1.3 (1.13, 1.49)
34e63 1.65 (1.45, 1.89)
64 3.53 (3.13, 3.98)
Medication
Prednisone 2.29 (2.05, 2.57)
Isosorbide di- or mononitrate 1.77 (1.52, 2.06)
Furosemide 3.15 (2.9, 3.41)
ACE inhibitors 1.58 (1.46, 1.71)
Verapamil, diltiazem, or felodipine 1.36 (1.24, 1.48)
Antidepressants 1.9 (1.75, 2.06)
Oral narcotics 2.32 (2.12, 2.54)
Benzodiazepine 1.89 (1.74, 2.06)
Pulmonary medications 3.03 (2.7, 3.38)
Medical services received in prior year
Chemotherapy or radiation treatment 8.02 (6.86, 9.37)
Home health care 3.59 (3.29, 3.91)
Optometrist 0.82 (0.76, 0.88)
Hospitalization
None Referent
1þ 2.24 (2.07, 2.43)
Total specialist visits
None Referent
1þ 1.88 (1.75, 2.02)
Days with one or more outpatient visits
0e3 Referent
4e6 0.96 (0.85, 1.09)
7e12 1.11 (0.99, 1.24)
13þ 1.86 (1.67, 2.06)
Medical diagnosis in previous year
Asthma 1.2 (1.02, 1.42)
Congestive heart failure 3.43 (3.13, 3.76)
COPD 2.49 (2.28, 2.72)
Dementia 2.81 (2.48, 3.2)
Depression 1.63 (1.43, 1.87)
Peripheral vascular disease 2.26 (1.97, 2.61)
Pneumonia 2.65 (2.36, 2.98)
Renal Disease 4.68 (4.05, 5.4)
Diabetes
None Referent
Untreated 1.19 (0.99, 1.42)
Oral medications only 1.4 (1.19, 1.64)
Insulin 2.7 (2.17, 3.34)
Complication 2.14 (1.86, 2.47)
Cancer severity
None Referent
Cancer 1.29 (1.17, 1.41)
Severe/multiple myeloma 8.51 (7.65, 9.47)
Laboratory values in previous year
Lowest albumin value
!3.39 0.25 (0.21, 0.3)
3.4e3.59 1.64 (1.35, 1.99)
3.6e3.89 0.56 (0.47, 0.66)
3.9þ Referent
Laboratory data not assessed 0.2 (0.17, 0.24)
Highest creatinine value
!1 Referent
1.1e1.39 1.79 (1.6, 2)
1.4e2.39 5.6 (4.81, 6.52)
(Continued )
Table 4. Continued
Full sample characteristics
Association with death
Odds ratio (95% CI)
2.4þ 0.95 (0.85, 1.07)
Laboratory data not assessed 0.65 (0.59, 0.73)
Lowest hematocrit value
!29 1.98 (1.68, 2.33)
29e33.9 0.25 (0.22, 0.28)
34e37.9 0.34 (0.29, 0.4)
38e39.9 0.54 (0.47, 0.61)
40þ Referent
Laboratory data not assessed 0.22 (0.2, 0.25)
Abbreviations: CI, confidence interval; ACE, angiotensin-
converting enzyme; COPD, chronic obstructive pulmonary disease.
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cohort sampled from a larger cohort using a two-phase
stratified design. Subcohort analyses are then inverse prob-
ability weighted based on the sampling probabilities (i.e.,
using HorvitzeThompson estimation) so that subcohort in-
ference reflects the larger cohort and is thus generalizable
to the original population [25]. However, weights based
only on the stratifying factors do not generally use all the
available information on the larger cohort, information
known as auxiliary data (V) [26]. To increase precision,
standard weights can be adjusted using V so that the ob-
served total of V in the larger cohort equals the weighted
total of V in the subcohort, while keeping the adjustment
as small as possible. This induced dependence of the
weights on V, measured on the full cohort, drives the effi-
ciency gain and is known as calibration [27,28]. To avoid
confusion with the previously described imputation ap-
proach, which has also been called calibration, we refer
to this reweighting method using an alternative survey ter-
minology: generalized raking [24].
To implement raking in the influenza VE example, we fit
a weighted Cox model in the validation sample that es-
timated the RR of death for those vaccinated vs. not vacci-
nated, adjusted for PSgs, where the weights were estimated
as follows: (1) define initial weights as the inverse probabil-
ity of inclusion in the ACT validation cohort, and estimate
them using logistic regression with age, gender, and their
interaction as predictors, as if the ACT cohort was drawn
from the full sample using an age- and gender-stratified de-
sign; and (2) adjust the initial weights by using the addi-
tional auxiliary information, PSep, available on all full
cohort members. Instead of directly using PSep as the rak-
ing variable (i.e., instead of using V5 PSep), we used a vari-
able based on PSep called a deltaebeta, a quantity that
reflects the estimated influence of each subject in a Cox re-
gression and has been shown to estimate the optimally ef-
ficient choice of V [23,25,26]. We note that although the
initial weights in step 1 were based only on age and gender
(to reflect stratifying factors that are commonly used in
practice in two-phase designs), the final weights used in
step 2 for reweighting depend on all the auxiliary database
Table 5. Age- and gender-adjusted odds ratios of associations between
supplemental confounders and death in the validation sample
Characteristics
Association with death
Odds ratio (95% CI)
Race
White 1.6 (0.59, 4.37)
Perceived health
Poor 6.63 (1.61, 27.38)
Fair 4.31 (1.29, 14.42)
Good 2.03 (0.61, 6.75)
Very good 1.92 (0.56, 6.6)
Excellent Referent
BMI
Underweight Referent
Adequate 2.41 (0.61, 9.51)
Overweight 1.09 (0.62, 1.94)
Obese 1.09 (0.52, 2.28)
Unavailable 3.23 (1.4, 7.44)
Lives alone 0.63 (0.37, 1.07)
Any exercise in past 12 mo 0.48 (0.3, 0.76)
Frailty measures
Frail grip strength 1.52 (0.92, 2.5)
Frail walking speed 2.73 (1.61, 4.62)
Able to walk around house
No difficulty Referent
Some difficulty 1.25 (0.62, 2.52)
A lot of difficulty/unable 1.81 (0.66, 4.97)
Able to walk half a mile
No difficulty Referent
Some difficulty 2.18 (1.08, 4.4)
A lot of difficulty/unable 2.73 (1.6, 4.65)
Able to walk upstairs
No difficulty Referent
Some difficulty 2.2 (1.22, 3.96)
A lot of difficulty/unable 2.58 (1.4, 4.74)
Able to get out of bed/chair
No difficulty Referent
Some difficulty 0.92 (0.49, 1.73)
A lot of difficulty/unable 2.48 (1.15, 5.35)
Able to feed oneself
No difficulty Referent
Some difficulty 3.77 (1.67, 8.51)
Able to dress oneself
No difficulty Referent
Some difficulty 1.06 (0.41, 2.77)
A lot of difficulty/unable 7.09 (3.16, 15.93)
Able to bathe oneself
No difficulty Referent
Some difficulty 1.9 (0.85, 4.25)
A lot of difficulty/unable 3.68 (1.77, 7.64)
Able to use toilet
No difficulty Referent
Some difficulty 0.38 (0.05, 2.66)
A lot of difficulty/unable 7.67 (3.33, 17.66)
Receives home health care 2.25 (1.26, 4.02)
Uses handivan 0.21 (0.03, 1.61)
Difficulty on any IADLitem 2.44 (1.52, 3.94)
Difficulty on any ADL item 1.31 (0.8, 2.14)
Medical diagnosis in previous year
Congestive heart failure 2.56 (1.4, 4.67)
Hearth rhythm problems 1.35 (0.85, 2.15)
Heart condition 1.61 (0.99, 2.6)
Diabetes
None Referent
(Continued )
Table 5. Continued
Characteristics
Association with death
Odds ratio (95% CI)
Untreated 1.16 (0.3, 4.46)
With oral medication 2.59 (0.98, 6.83)
With complications 1.12 (0.41, 3.09)
Parkinson’s disease 1.35 (0.51, 3.61)
Chronic lung condition 1.68 (1.01, 2.79)
Acute lung infection 1.4 (0.87, 2.25)
Kidney
None Referent
Disease 1.19 (0.58, 2.43)
Failure 4.61 (1.55, 13.73)
Autoimmune disorder 0.34 (0.09, 1.32)
Any fractures 1.27 (0.62, 2.6)
Dementia 4.47 (2.58, 7.75)
Cognitive Abilities Screening Instrument Score
0e89 Referent
90e94 0.39 (0.21, 0.73)
95e96 0.4 (0.19, 0.87)
97þ 0.4 (0.2, 0.8)
CES-D score
0 Referent
1e3 0.85 (0.44, 1.63)
4e6 1.05 (0.46, 2.39)
6þ 1.51 (0.83, 2.76)
Abbreviations: CI, confidence interval; BMI, body mass index;
IADL, instrumental activities of daily living; ADL, activities of daily liv-
ing; CES-D, Center for Epidemiologic Studies Depression Scale.
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available database information.3. Results
3.1. Characteristics of the study years and cohorts
The full sample and validation sample cohorts com-
prised approximately 44,000 and 1,000 seniors each year
who contributed 86,400 and 1,936 person-years during
the 2-year study period, respectively (Table 1). Annual in-
fluenza vaccine coverage was approximately 71% and
76% in the full and validation samples, respectively, and
about 3e4% died each year in each cohort. The percent
who died in the periods before, during, and after influenza
season were 0.9%, 0.8%, and 1.6%, respectively, with the
highest percent observed after influenza season, which
was roughly twice as long as the other periods. Most vacci-
nated seniors received vaccine in November of each study
year (Fig. 1). Tables 2 and 3 show the characteristics of
the full and validation sample cohorts based on database
confounders included in the PSep and the supplemental
confounders included in the PSgs, respectively. About
60% of members in both cohorts were female, and the full
sample was slightly younger than the validation sample.
Tables 4 and 5 show the ORs and 95% confidence intervals
(CIs) quantifying the magnitude of the age- and gender-
adjusted association between each confounder and death
Fig. 2. Relative risk of all-cause mortality for vaccinated seniors com-
pared with unvaccinated seniors in intervals before, during, and after
influenza season, unadjusted and adjusted based on three statistical
methods. PS, propensity score.
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based on both database and validation sample information.3.2. Comparisons of VE estimates across approaches
Estimates and 95% CIs of the RR of death associated
with influenza vaccination obtained using each of the four
approaches (unadjusted, na€ıve, imputation, and reweight-
ing) in each time period (before, during, and after influenza
season) are shown in Fig. 2. The RRs were lowest (!0.50)
in the period before influenza season and then increasedFig. 3. Diagnostic scatterplot with fitted regression lines estimating
the strength of the association between error-prone and gold-
standard propensity scores within the validation sample.steadily (to 0.50e0.70 during and O0.80 after influenza
season). Unadjusted and na€ıvely adjusted estimates were
similar to one another across all time periods. Estimates
based on imputation or reweighting were also comparable
to one another in all time periods, but consistently closer
to the null (i.e., RR5 1.0) compared with the unadjusted
and na€ıvely adjusted estimates. No approach correctly esti-
mated a null RR5 1.0 in the control period before influenza
season, although the preinfluenza estimates based on im-
putation and reweighting were closer to 1.0 than the na€ıvely
adjusted RR, indicating that bias was somewhat reduced
using methods that incorporated the validation confounder
data. The quality of the imputation and reweighting is char-
acterized in Fig. 3. This scatterplot with fitted regression
lines estimating the association betweenPSep and PSgswithin
the validation sample shows modest correlation (r5 0.60)
and wide variability in PSgs for each PSep.4. Discussion
The association between influenza vaccination and risk
of all-cause mortality is a useful example for studying prob-
lems of confounding in treatment effectiveness studies that
rely on administrative databases [3], as strong confounding
is present, and there is a natural control period before influ-
enza season that can be used to assess bias [10,29]. In this
study, we leveraged existing data from two prior cohort
studies to explore the utility of using two methods (imputa-
tion and reweighting) that integrate additional confounder
data from a validation sample to reduce confounding bias
in influenza VE estimates that adjust only for information
available in database sources. Using the control period
before influenza season as a gauge, we found that both
methods modestly reduced but did not completely eliminate
the bias compared with na€ıvely adjusted estimates that did
not use the validation sample confounder data. The mag-
nitude of the bias reduction was comparable in both
approaches.
Use of validation sample methods can enhance health
care database studies, but our results suggest that their suc-
cess in practice depends on many factors and assumptions.
The key bias-reducing factor for either imputation or re-
weighting is the ability to measure the important con-
founders in the validation sample. Both methods also rely
on the comparability of the validation and full samples,
which is guaranteed if the validation sample is designed
as a probability-sampled subcohort. Unbiased estimation
for imputation further depends on the correctness of the
model used to impute the gold-standard confounder data
from the error-prone information, whereas reweighted esti-
mates are robust to this assumption (i.e., they will be no
worse than estimates based only on the validation sample,
even if this model is incorrect). In both methods, precision
will improve as the amount of information in the validation
sample increases, which can occur either with larger
S120 J.C. Nelson et al. / Journal of Clinical Epidemiology 66 (2013) S110eS121validation sample sizes or with increases in the strength of
the association between the gold standard and error-prone
confounders. Lastly, the imputation approach has several
additional assumptions, including the conditional indepen-
dence of the error-prone confounders from outcomes, given
the gold-standard confounders (i.e., the surrogacy assump-
tion) [22,30]. Our specific application of imputation, which
was designed to be consistent with the propensity score
calibration method, involved a propensity score summary
measure rather than a single measured covariate, and this
raises additional technical issues many of which have been
discussed by Lunt et al. [31]. Implementation of the propen-
sity score calibration approach could be further enhanced by
performing multiple rather than single imputation.
The influenza VE example we used in this study was
advantageous for several reasons. First, there is a well-
defined control period during which bias can be assessed.
Also, the potential for other sources of bias is relatively
small. Outcome misclassification was minimized because
in addition to capturing mortality data directly from
GHC databases, we linked to state mortality records and
thus obtained information even if a subject disenrolled
from GHC. Exposure misclassification is also likely to
be small because vaccination coverage rates in the GHC
population have been found to closely reflect average cov-
erage rates among those 65 years and older in Washington
State [32]. Reasons for high accuracy of exposure data in-
clude the following: (1) the electronic vaccination registry
at GHC is well established, dating back to 1991 when it
was created for the Vaccine Safety Datalink Project [33],
and is routinely monitored for quality assurance; (2)
GHC reciprocally shares data with the Washington State
Immunization Information System and so captures vaccine
data on seniors vaccinated at outside institutions; and (3)
GHC databases will contain vaccinations received by se-
niors during hospital stays if the hospital filed a claim
for payment for the vaccination.
However, the influenza VE application was also limited in
several ways. One major challenge is the presence of a selec-
tion mechanism for influenza vaccination that is extremely
difficult to measure. Although the ACT validation con-
founders included a variety of disease severity and functional
status measures that were geared to address unmeasured
frailty, the reasons for selective receipt of preventive thera-
pies such as influenza vaccine in seniors are clearly complex
and difficult to measure, and this has been observed in prior
studies [10e12]. In many settings, confounding by frailty
could instead be addressed by using an active vs. an unex-
posed comparator, but an active comparator is not readily
available for influenza vaccine. Trimming a small proportion
of those treated contrary to prediction has been proposed as
another method to address unmeasured confounding owing
to frailty, but we did not explore that option in this analysis
[34]. Second, comparability between the full and validation
cohorts was imperfect, reducing the generalizability to the
full sample of the validation sample model that related thegold standard and error-prone propensity scores. More im-
portantly, the relatively rigorous nature of the ACT inter-
views and examinations may have resulted in frail and
demented seniors (the group most plausibly responsible for
the much of the unmeasured confounding) being underrepre-
sented in the validation sample, which would limit the ability
to remove confounding by frailty.A third limitation is that the
quality of the model relating the gold standard to the error-
prone information in the validation sample was somewhat
weak, with wide variability in the gold-standard propensity
score for each value of the error-prone propensity score, sug-
gesting relatively limited predictive ability of the database
information. Fourth, the validation sample sizewas relatively
small and themortality outcomewas rare, which reduced sta-
tistical power.
Our results support further exploration of validation
sampling methods, such as imputation and reweighting, to
improve the accuracy of findings from health care database
studies. Although similar recommendations have been
made previously [26,35e37], and software is readily avail-
able (widely for imputation and comprehensively in R for
survey procedures [38]), such methods remain relatively
underused. One challenge when studying treatment effec-
tiveness beyond influenza vaccine is that there are limited
methods to evaluate the performance of more sophisticated
confounder adjustment techniques, like those that incorpo-
rate validation data. Unlike the case with influenza vaccine,
there may not be a readily available control period during
which the association between treatment exposure and out-
come is known. If this is the case, one cannot determine
with certainty when a method gets the ‘‘right’’ answer or
when one method outperforms another. Efficacy estimates
from randomized controlled trials (RCTs) may give some
indication of the ‘‘truth,’’ but they may also truly differ
from observational effectiveness results owing to major dif-
ferences among study populations and between highly con-
trolled RCTs and ‘‘real-world’’ observational settings.
Without clear gold-standard estimates of effectiveness in
practice for most exposures, a balance of simulation studies
(where truth can be generated) and example applications
(where the complexities of real data are present) is needed
to more fully understand the optimal implementation and
settings for use of validation methods in practice.Acknowledgments
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